| |||||||||||||||
Former Names FVB/N-Tg(MHCAtTA)6Smbf/J (Changed: 21-NOV-07 ) Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Generation N8+N1p Donating Investigator Glenn Fishman, NYU School of Medicine Appearance
albino
Related Genotype: Tyrc/TyrcImportant Note
This strain is homozygous for the retinal degeneration allele Pde6brd1.Description
This strain expresses the tetracycline-controlled transactivator protein (tTA) under the regulatory control of the rat alpha myosin heavy chain promoter, which directs expression of tTA, specifically, in cardiac myocytes. When these Myh6-tTA (also called 2.9alphatTA or MHCAtTA) transgenic mice are mated to a second transgenic strain carrying a gene of interest coupled to a tetracycline-responsive promoter element (TRE), conditional expression of the target gene in cardiac myocytes may be controlled by the administration of tetracycline or doxycycline.Development
A transgene in which ~ 2.9kb of 5' flanking sequence from the rat alpha myosin heavy chain gene drives expression of the tetracycline-controlled transactivator (tTA) was microinjected into C57BL/6xCBA F1 hybrid pronuclei. Subsequently, the strain was backcrossed to FVB/N for at least 8 generations.
| Control | ||
|---|---|---|
| Noncarrier | ||
| 001800 FVB/NJ | ||
| Considerations for Choosing Controls | ||
Strains carrying Pde6brd1 allele
View Strains carrying Pde6brd1 (74 strains)
Strains carrying other alleles of Pde6b
004297 B6.CXB1-Pde6brd10/J 005252 B6EiC3Sn.BLiA-Ts(1716)65Dn/DnJ 003647 B6EiC3Sn.BLiAF1 002802 C3.BLiA Pde6b+-Krd/J 001979 C3A.BLiA-Pde6b+.O20-Prph2Rd2/J 001912 C3A.BLiA-Pde6b+/J 003648 C3Sn.BLiA-Pde6b+/Dn 004766 C57BL/6J-Pde6brd1-2J/J 004828 FVB.129P2-Pde6b+ Tyrc-ch/AntJ 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J View Strains carrying other alleles of Pde6b (10 strains)
Strains carrying other alleles of tTA
007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003767 B6.Cg-Tg(Eno2tTA)5021Nes/J 003763 B6.Cg-Tg(Eno2tTA)5030Nes/J 005964 B6.Cg-Tg(GFAP-tTA)110Pop/J 002618 B6.Cg-Tg(MMTVtTA)1Mam/J 008284 B6.Cg-Tg(Scg2-tTA)1Jt/J 006361 B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J 003563 B6.Cg-Tg(tTALap)5Bjd/J 002709 B6;C3-Tg(TettTALuc)1Dgs/J 003010 B6;CBA-Tg(Camk2a-tTA)1Mmay/J 008344 B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J 010573 B6;SJL-Tg(Prl-tTA)6-5Jek/J 008082 B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J 005625 FVB-Tg(Pcp2-tTA)3Horr/J 006209 FVB.Cg-Tg(Tal1-tTA)19Dgt/J 005942 FVB/N-Tg(Pf4-tTA/VP16)42Kra/J 004937 NOD.Cg-Tg(Ins2-tTA)1Doi/DoiJ 006999 STOCK Dbttm1Geh Tg(tTALap)5Bjd Tg(tetO-DBT)A1Geh/J 009606 STOCK Tg(Six2-EGFP/cre)1Amc/J 003271 STOCK Tg(tTAhCMV)3Bjd/J 003275 STOCK Tg(tetL)1Bjd/J 003274 STOCK Tg(tetNZL)2Bjd/J View Strains carrying other alleles of tTA (22 strains)
Tet Expression Systems
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Pde6brd1 relatedResearch Tools
Cardiovascular Research
Tet Expression Systems
tTA/rtTA Expressing Strains
Mouse/Human Gene Homologs
retinitis pigmentosa, autosomal recessive
Sensorineural Research
Retinal Degeneration
| Allele Symbol | Tg(Myh6-tTA)6Smbf | ||
|---|---|---|---|
| Allele Name | transgene insertion 6, Section of Myocardial Biology - Fishman Lab | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | 2.9alphatTA; Tg(MHCAtTA)6Smbf; alphaMHC-tTA; | ||
| Mutation Made By | Glenn Fishman, NYU School of Medicine | ||
| Strain of Origin | (C57BL/6 x CBA)F1 | ||
| Site of Expression | Expresses tTA in cardiac myocytes. | ||
| Expressed Gene | tTA, tetracycline-controlled transactivator, E. coli | ||
| The tetracycline-resistance gene (TetR), arose from chemically mutated Escherichia coli genome which was screened for tetracycline dependence (Gossen and Bujard, 1992). TetR was fused at the C-terminus with the viral co-activator, virion protein 16 of the herpes simplex virus (VP-16). The tetracycline-inhibitable transcription factor is a component of a bigenic system that allows doxycycline (a tetracycline analog) regulatable expression of genes that are under the direction of the tetracycline responsive promoter (TetOp)promoter. | |||
| Promoter | Myh6, myosin, heavy chain 6, cardiac muscle, alpha, rat | ||
| General Note | Transgenic line 6 showed the strongest cardiac transgene expression and was used for analysis. | ||
| Molecular Note | The transgene consists of a rat Myh6 promoter and a tetracycline transactivator sequence. Transgene expression in cardiac tissue was confirmed by Northern blot analysis. 2.9 kb of rat Myh6 promoter sequences directs transgene expression in the heart starting at embryonic day E7.5. [MGI Ref ID J:82692] | ||
| Allele Symbol | Pde6brd1 | ||
| Allele Name | retinal degeneration 1 | ||
| Allele Type | Spontaneous | ||
| Common Name(s) | Pdebrd1; rd; rd-1; rd1; rodless retina; | ||
Genotyping Protocols
Tg(tTA), Melt Curve Analysis
Tg(tTA), QPCR
Tg(tTA), Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Yu Z; Redfern CS; Fishman GI. 1996. Conditional transgene expression in the heart. Circ Res 79(4):691-7. [PubMed: 8831492] [MGI Ref ID J:82692]
Bowman JC; Steinberg SF; Jiang T; Geenen DL; Fishman GI; Buttrick PM. 1997. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 100(9):2189-95. [PubMed: 9410895] [MGI Ref ID J:43986]
Ward NL; Van Slyke P; Sturk C; Cruz M; Dumont DJ. 2004. Angiopoietin 1 expression levels in the myocardium direct coronary vessel development. Dev Dyn 229(3):500-9. [PubMed: 14991706] [MGI Ref ID J:88848]
Tg(Myh6-tTA)6Smbf relatedBaker AJ; Redfern CH; Harwood MD; Simpson PC; Conklin BR. 2001. Abnormal contraction caused by expression of G(i)-coupled receptor in transgenic model of dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 280(4):H1653-9. [PubMed: 11247776] [MGI Ref ID J:128598]
Barandon L; Dufourcq P; Costet P; Moreau C; Allieres C; Daret D; Dos Santos P; Daniel Lamaziere JM; Couffinhal T; Duplaa C. 2005. Involvement of FrzA/sFRP-1 and the Wnt/frizzled pathway in ischemic preconditioning. Circ Res 96(12):1299-306. [PubMed: 15920021] [MGI Ref ID J:110294]
Bowman JC; Steinberg SF; Jiang T; Geenen DL; Fishman GI; Buttrick PM. 1997. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 100(9):2189-95. [PubMed: 9410895] [MGI Ref ID J:43986]
Burkard N; Rokita AG; Kaufmann SG; Hallhuber M; Wu R; Hu K; Hofmann U; Bonz A; Frantz S; Cartwright EJ; Neyses L; Maier LS; Maier SK; Renne T; Schuh K; Ritter O. 2007. Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility. Circ Res 100(3):e32-44. [PubMed: 17272813] [MGI Ref ID J:133706]
Callis TE; Pandya K; Seok HY; Tang RH; Tatsuguchi M; Huang ZP; Chen JF; Deng Z; Gunn B; Shumate J; Willis MS; Selzman CH; Wang DZ. 2009. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119(9):2772-86. [PubMed: 19726871] [MGI Ref ID J:152696]
Dor Y; Camenisch TD; Itin A; Fishman GI; McDonald JA; Carmeliet P; Keshet E. 2001. A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development 128(9):1531-8. [PubMed: 11290292] [MGI Ref ID J:68214]
Gao MH; Bayat H; Roth DM; Yao Zhou J; Drumm J; Burhan J; Hammond HK. 2002. Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function. Cardiovasc Res 56(2):197-204. [PubMed: 12393090] [MGI Ref ID J:132260]
Gellen B; Fernandez-Velasco M; Briec F; Vinet L; LeQuang K; Rouet-Benzineb P; Benitah JP; Pezet M; Palais G; Pellegrin N; Zhang A; Perrier R; Escoubet B; Marniquet X; Richard S; Jaisser F; Gomez AM; Charpentier F; Mercadier JJ. 2008. Conditional FKBP12.6 overexpression in mouse cardiac myocytes prevents triggered ventricular tachycardia through specific alterations in excitation-contraction coupling. Circulation 117(14):1778-86. [PubMed: 18378612] [MGI Ref ID J:153299]
Grunewald M; Avraham I; Dor Y; Bachar-Lustig E; Itin A; Jung S; Chimenti S; Landsman L; Abramovitch R; Keshet E. 2006. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124(1):175-89. [PubMed: 16413490] [MGI Ref ID J:115908]
Hirotani S; Zhai P; Tomita H; Galeotti J; Marquez JP; Gao S; Hong C; Yatani A; Avila J; Sadoshima J. 2007. Inhibition of glycogen synthase kinase 3beta during heart failure is protective. Circ Res 101(11):1164-74. [PubMed: 17901358] [MGI Ref ID J:142787]
Huang L; Wolska BM; Montgomery DE; Burkart EM; Buttrick PM; Solaro RJ. 2001. Increased contractility and altered Ca(2+) transients of mouse heart myocytes conditionally expressing PKCbeta. Am J Physiol Cell Physiol 280(5):C1114-20. [PubMed: 11287324] [MGI Ref ID J:128800]
Lee P; Morley G; Huang Q; Fischer A; Seiler S; Horner JW; Factor S; Vaidya D; Jalife J; Fishman GI. 1998. Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A 95(19):11371-6. [PubMed: 9736743] [MGI Ref ID J:128617]
May D; Gilon D; Djonov V; Itin A; Lazarus A; Gordon O; Rosenberger C; Keshet E. 2008. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A 105(1):282-7. [PubMed: 18162550] [MGI Ref ID J:131069]
McCloskey DT; Turcato S; Wang GY; Turnbull L; Zhu BQ; Bambino T; Nguyen AP; Lovett DH; Nissenson RA; Karliner JS; Baker AJ. 2008. Expression of a Gi-coupled receptor in the heart causes impaired Ca2+ handling, myofilament injury, and dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 294(1):H205-12. [PubMed: 17965283] [MGI Ref ID J:132451]
McCloskey DT; Turnbull L; Swigart PM; Zambon AC; Turcato S; Joho S; Grossman W; Conklin BR; Simpson PC; Baker AJ. 2005. Cardiac transgenesis with the tetracycline transactivator changes myocardial function and gene expression. Physiol Genomics 22(1):118-26. [PubMed: 15797971] [MGI Ref ID J:99311]
Mungrue IN; Gros R; You X; Pirani A; Azad A; Csont T; Schulz R; Butany J; Stewart DJ; Husain M. 2002. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 109(6):735-43. [PubMed: 11901182] [MGI Ref ID J:132082]
Redfern CH; Degtyarev MY; Kwa AT; Salomonis N; Cotte N; Nanevicz T; Fidelman N; Desai K; Vranizan K; Lee EK; Coward P; Shah N; Warrington JA; Fishman GI; Bernstein D; Baker AJ; Conklin BR. 2000. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc Natl Acad Sci U S A 97(9):4826-31. [PubMed: 10781088] [MGI Ref ID J:107363]
Sainte-Marie Y; Nguyen Dinh Cat A; Perrier R; Mangin L; Soukaseum C; Peuchmaur M; Tronche F; Farman N; Escoubet B; Benitah JP; Jaisser F. 2007. Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block. FASEB J 21(12):3133-41. [PubMed: 17517920] [MGI Ref ID J:134842]
Schiekofer S; Shiojima I; Sato K; Galasso G; Oshima Y; Walsh K. 2006. Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure. Physiol Genomics 27(2):156-70. [PubMed: 16882883] [MGI Ref ID J:113653]
Shiojima I; Sato K; Izumiya Y; Schiekofer S; Ito M; Liao R; Colucci WS; Walsh K. 2005. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115(8):2108-18. [PubMed: 16075055] [MGI Ref ID J:100144]
Tian R; Miao W; Spindler M; Javadpour MM; McKinney R; Bowman JC; Buttrick PM; Ingwall JS. 1999. Long-term expression of protein kinase C in adult mouse hearts improves postischemic recovery. Proc Natl Acad Sci U S A 96(23):13536-41. [PubMed: 10557356] [MGI Ref ID J:58525]
Tirziu D; Chorianopoulos E; Moodie KL; Palac RT; Zhuang ZW; Tjwa M; Roncal C; Eriksson U; Fu Q; Elfenbein A; Hall AE; Carmeliet P; Moons L; Simons M. 2007. Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest 117(11):3188-97. [PubMed: 17975666] [MGI Ref ID J:127379]
Turnbull L; Zhou HZ; Swigart PM; Turcato S; Karliner JS; Conklin BR; Simpson PC; Baker AJ. 2006. Sustained preconditioning induced by cardiac transgenesis with the tetracycline transactivator. Am J Physiol Heart Circ Physiol 290(3):H1103-9. [PubMed: 16243914] [MGI Ref ID J:106717]
Voskas D; Babichev Y; Ling LS; Alami J; Shaked Y; Kerbel RS; Ciruna B; Dumont DJ. 2008. An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice. J Leukoc Biol 84(1):59-67. [PubMed: 18443190] [MGI Ref ID J:137745]
Colony Maintenance
Breeding & Husbandry When mating to tet responder animals, doxycycline should be administered to the female to avoid an embryonic lethal phenotype. This strain is fed normal chow diet. Expected coat color from breeding is "Albino."
| Pricing for USA, Canada and Mexico shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $1900.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
| Pricing for International shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $2470.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
| Standard Supply | Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Important Note | |
| This strain is homozygous for the retinal degeneration allele Pde6brd1. | |
| Control | ||
|---|---|---|
| Noncarrier | ||
| 001800 FVB/NJ | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
For additional Licensing and Use Restrictions view the link(s) below:
- Strain(s) not available to companies or for-profit entities.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.